Entasis Therapeutics Inc (ETTX):製薬・医療:M&Aディール及び事業提携情報

GlobalDataが発行した調査報告書(DATA904C11019)
◆英語タイトル:Entasis Therapeutics Inc (ETTX) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA904C11019
◆発行会社(リサーチ会社):GlobalData
◆発行日:2018年11月
◆ページ数:43
◆レポート形式:英語 / PDF
◆納品方法:Eメール
◆調査対象地域:アメリカ
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送いたしますので、請求書発行日より2ヶ月以内に銀行振込にて支払をお願いします。
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規代理店です。同社発行の市場リサーチレポート及びリサーチサービスに関するお問い合わせは弊社までお願い致します。GlobalData社の概要及び新刊レポートはこちらでご確認いただけます。

【レポートの概要】

Summary
Entasis Therapeutics Inc (Entasis) is a drug development company that discovers and develops anti-infective therapies for drug-resistant bacterial infections. The company’s pipeline products include ETX2514, ETX0282, ETX0914 and Zoliflodacin. Its ETX2514 is a potent inhibitor of class A, C, and D beta-lactamases intended to treat serious gram-negative infections. Entasis’ ETX0914, is an oral antibiotic for the treatment of uncomplicated gonorrhoea. The company’s pipeline products are used to treat multidrug-resistant gram-negative infections such as pseudomonas aeruginosa, acinetobacter baumanii, carbapenem-resistant enterobacteriaceae, and neisseria gonorrhoeae, among others. It also develops robust clinical and pre-clinical pipeline of medicines. Entasis is headquartered in Waltham, Massachusetts, the US.

Entasis Therapeutics Inc (ETTX) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
Entasis Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Entasis Therapeutics Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Entasis Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Entasis Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
Entasis Therapeutics Inc, Medical Devices Deals, 2012 to YTD 2018 10
Entasis Therapeutics Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11
Entasis Therapeutics Inc, Pharmaceuticals & Healthcare, Deal Details 12
Venture Financing 12
Entasis Therapeutics Raises Additional USD32 Million in Series B-1 Financing 12
Entasis Therapeutics Raises USD50 Million in Series B Financing 14
Entasis Therapeutics Raises USD40 Million in Series A Venture Financing 15
Partnerships 16
Entasis Therapeutics and Global Antibiotic Research & Development Enter into Partnership 16
Licensing Agreements 17
Zai Lab Enters into Licensing Agreement with Entasis Therapeutics 17
Equity Offering 18
Entasis Therapeutics Prices IPO of Shares for USD75 Million 18
Entasis Therapeutics Spin Out from AstraZeneca 20
Entasis Therapeutics Inc – Key Competitors 21
Entasis Therapeutics Inc – Key Employees 22
Entasis Therapeutics Inc – Locations And Subsidiaries 23
Head Office 23
Recent Developments 24
Financial Announcements 24
Nov 14, 2018: Entasis Therapeutics reports third quarter 2018 financial results 24
Corporate Communications 26
May 01, 2018: Entasis Therapeutics Appoints David C. Hastings to Board of Directors 26
Apr 10, 2017: Entasis Appoints Mike Gutch as Chief Financial Officer and Chief Business Officer 27
Product News 28
06/30/2017: Entasis Publishes Data Highlighting the Potent and Differentiated Activity of ETX2514 Combinations against Drug Resistant Gram-negative Bacteria Including Acinetobacter and Pseudomonas 28
06/07/2017: Entasis Therapeutics Presents Data on ETX2514 at ASM Microbe 2017 29
06/06/2018: Entasis Therapeutics to Present Data on ETX0282 at ASM Microbe 2018 30
05/22/2017: Entasis Therapeutics to Present Data on ETX1317 at ASM Microbe 2017 31
05/22/2017: Entasis Therapeutics to Present Data on ETX2514 at ASM Microbe 2017 32
05/22/2017: Entasis Therapeutics to Present Data on ETX0282 at ASM Microbe 2017 33
Clinical Trials 34
Aug 14, 2018: Entasis Therapeutics announces positive topline results from phase 2 trial of ETX2514SUL in patients with complicated urinary tract infections including acute pyelonephritis 34
Jun 06, 2018: Entasis Therapeutics to Present Data on ETX2514 at ASM Microbe 2018 35
May 14, 2018: Entasis Therapeutics Initiates Clinical Studies of the Oral Extended-Spectrum Beta-Lactamase Inhibitor ETX0282 37
Oct 12, 2017: Entasis Therapeutics Receives Second CARB-X Award, Providing up to $10.1 Million for Development of Non-Beta-lactam PBP Inhibitor Program 38
Oct 09, 2017: Entasis Therapeutics Highlights Positive Phase 1 Data for ETX2514 at IDWeek 2017, Announces Plans to Advance Combination with sulbactam (ETX2514SUL) into Phase 2 Trials 39
Sep 28, 2017: Entasis Therapeutics to Present Phase 1 Data on ETX2514 at IDWeek 2017 40
Jun 07, 2017: Entasis Therapeutics Presents Data on Third Drug Candidate, ETX0282, an Orally Available, Extended-Spectrum eta-lactamase Inhibitor, at ASM Microbe 2017 41
Apr 21, 2017: Entasis Therapeutics to Present Data on ETX2514SUL at 27th European Congress of Clinical Microbiology and Infectious Diseases 42
Appendix 43
Methodology 43
About GlobalData 43
Contact Us 43
Disclaimer 43

List of Tables
Entasis Therapeutics Inc, Pharmaceuticals & Healthcare, Key Facts 2
Entasis Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Entasis Therapeutics Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Entasis Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Entasis Therapeutics Inc, Deals By Therapy Area, 2012 to YTD 2018 9
Entasis Therapeutics Inc, Medical Devices Deals, 2012 to YTD 2018 10
Entasis Therapeutics Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11
Entasis Therapeutics Raises Additional USD32 Million in Series B-1 Financing 12
Entasis Therapeutics Raises USD50 Million in Series B Financing 14
Entasis Therapeutics Raises USD40 Million in Series A Venture Financing 15
Entasis Therapeutics and Global Antibiotic Research & Development Enter into Partnership 16
Zai Lab Enters into Licensing Agreement with Entasis Therapeutics 17
Entasis Therapeutics Prices IPO of Shares for USD75 Million 18
Entasis Therapeutics Spin Out from AstraZeneca 20
Entasis Therapeutics Inc, Key Competitors 21
Entasis Therapeutics Inc, Key Employees 22

List of Figures
Entasis Therapeutics Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Entasis Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Entasis Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Entasis Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Entasis Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Entasis Therapeutics Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7
Entasis Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Entasis Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
Entasis Therapeutics Inc, Medical Devices Deals, 2012 to YTD 2018 10

【免責事項】
http://www.globalresearch.jp/disclaimer

★リサーチレポート[ Entasis Therapeutics Inc (ETTX):製薬・医療:M&Aディール及び事業提携情報(Entasis Therapeutics Inc (ETTX) - Pharmaceuticals & Healthcare - Deals and Alliances Profile)]についてメールでお問い合わせはこちらでお願いします。

◆H&Iグローバルリサーチのお客様(例)◆